Objective To evaluate the first and second assay kits currently used in blood centers forscreeningHCV infected blood, and to providebasis for a better matchof the two assay kits.
Meanwhile, patients in European countries were denied access to the cancer screeningkits, because national health services were unwilling to meet the cost.